Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mallinckrodt purchases pain drug Roxicodone from Xanodyne

Executive Summary

Continuing to strengthen its portfolio in preparation for a spin off from Covidien PLC’s Covidien Ltd., Mallinckrodt LLC (branded and generic pain and addiction treatments) has acquired Roxicodone (oxycodone, 5, 15, and 30 mg dosages) from Xanodyne Pharmaceuticals Inc. (formerly focused on pain management). The transaction includes all rights to the drug’s NDA.

Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)
    • Product Purchase

Related Companies